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Progression (growth, invasion and metastasis) of solid tumours
requires, and is correlated with, the formation of microvessels, i.e.
angiogenesis (Folkman, 1995). Microvessels promote growth
because they convey nutrients and oxygen and remove catabo-
lites, while endothelial cells secrete paracrine growth factors for
tumour cells (Hamada et al, 1992). Microvessels facilitate inva-
sion because endothelial cells (at their tips) secrete several extra-
cellular matrix-degrading enzymes (Mignatti and Rifkin, 1993).
They also enable metastasis formation because an expanding
endothelial surface offers tumour cells more opportunities to
enter the circulation (Aznavoorian et al, 1993). Host inflamma-
tory cells, including macrophages, have also been shown to be
closely associated with progression because they stimulate both
growth and angiogenesis via paracrine mechanisms, and facilitate
invasion by secreting matrix-degrading enzymes (Hildenbrand
et al, 1995; Polverini, 1996).
There is only fragmentary evidence of the extent to which the
position is the same in haematological tumours. Angiogenesis is
correlated with tumour growth (S-phase fraction) in multiple
myelomas (Vacca et al, 1994) and with progression stages of
mycosis fungoides (Vacca et al, 1997), and it is readily observed in
B-cell and T-cell acute lymphoblastic leukaemia at diagnosis, but
not after treatment (Perez-Atayde et al, 1997).
This paper presents the results of an investigation on angiogen-
esis extent and macrophage density in benign lymphadenophathies
and in non-Hodgkin’s lymphomas of B-cell lineage (B-NHL)s
grouped according to well-defined pathways of progression.
MATERIALS AND METHODS
Tissues
Representative node samples of 71 B-NHLs and of 30 benign
lymphadenopathies were studied (Table 1). Approval was obtained
from the local ethics committee and with informed consent from
patients prior to therapy.
The reactive lymphoid hyperplasias displayed either follicular
hyperplasia (human immunodeficiency virus lymphadenitis,
rheumatoid lymphadenopathies), paracortical hyperplasia (dermato-
pathic lymphadenopathies), or mixed hyperplasia (Epstein–Barr
virus, cytomegalovirus and Toxoplasma gondii lymphadenitides);
the atypical forms displayed follicular hyperplasia.
Samples were formalin fixed and paraffin embedded immedi-
ately after surgical removal and sectioned for histopathology,
immunohistochemistry and electron microscopy.
Antibodies and immunohistochemistry
A three-layer biotin–avidin–alkaline phosphatase system was used
as described previously (Vacca et al, 1997). Briefly, 8-mm sections
were deparaffinized by the xylene–ethanol sequence, treated with
0.1% trypsin (Sigma Chemical Co, St Louis, MO, USA) and
sequentially incubated with: (1) primary antibodies, i.e. murine
monoclonal antibodies (MAbs) against the endothelial cell marker
factor VIII (MAb M616, Dako, Glostrup, Denmark), the mono-
cyte–macrophage marker CD68 (MAb KP1, Dako), or against
several markers of T-cells (CD2, CD3, CD4, CD7 and CD8) and
B-cells (k and l Ig chains, CD19, CD20, CD22 and HLA-DR, all
from Becton-Dickinson, Sunnyvale, CA, USA) for lineage typing
of NHLs as described previously (Vacca et al, 1996); in negative
control sections, the MAbs were replaced by an unrelated mono-
clonal IgG1 produced by the murine myeloma P3X63Ag8 (Vacca
et al, 1997); (2) a secondary antibody, i.e. biotin-labelled horse
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alkaline phosphatase conjugate (Promega, Madison, WI, USA).
After the sections were exposed to Fast blue chromogenic solution
(Promega) and brown staining was developed, they were
washed, weakly counterstained with Gill’s haematoxylin No. 2
(Polysciences, Warrington, PE, USA), dehydrated with the ethanol
sequence, mounted in Eukitt, coded and examined under a
double-headed photomicroscope (Leitz Dialux 20, Leitz, Wetzlar,
Germany) by two investigators.
Microvessel and macrophage counts
Four to six 200´ fields covering the whole of each of three non-
adjacent sections (every fourth section within 12 serial sections)
per sample were examined with a 144-intersection point square
reticulum (0.78 mm2) inserted in the eyepiece.
Care was taken to identify microvessels (capillaries and small
venules) as transversally sectioned tubes with a single layer of
endothelial cells, either without or with a lumen (not exceeding
10 mm), and either without or with a thin basement membrane. Each
assessment was agreed upon in turn. These stained microvessels,
useful markers of angiogenesis (Folkman et al, 1989), were counted
with a planimetric point-count method (Elias and Hyde, 1983)
modified to restrict counting to transversally cut microvessels occu-
pying the reticulum intersection points (Ribatti et al, 1998). As their
diameter was smaller than the distance between adjacent points,
only one such microvessel could occupy a given point. It was thus
sufficiently certain that a given microvessel was counted only once,
even if several of its section planes were present. The method (Elias
and Hyde, 1983) also makes allowances for the heterogeneous
distribution of microvessels in tissues. Indeed, in line with other
(Kittas et al, 1985) and our own observations (Vacca et al, 1996),
lymphadenopathies display very few microvessels in follicles.
These mainly surround the mantle zone, and are scattered
throughout the paracortical area and cords of lymphocytes. In follic-
ular low- and intermediate-grade B-NHLs, microvessels are also
very rare in follicles, but they are numerous in uninvolved tissue
both between and in areas representing either diffuse infiltration or
tissue shown as uninvolved by immunohistochemistry. Low-grade
small lymphocytic, diffuse intermediate-grade, and high-grade
B-NHLs display microvessels irregularly scattered throughout the
tumour tissue. As the whole of each of three non-adjacent sections
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Table 1 Clinical and histological characteristics of the patients
B-cell lymphomas (REAL classification)a 71
Small lymphocytic 12
Average age (males/females) 54 (8/4)
Stage I–II/III–IV (A/B status)b 3/9 (9/3) WF low-graded
(n = 27)
Follicle cell lymphoma 25
Average age (males/females) 58 (18/7) Kiel low-graded
Stage I–II/III–IV (A/B status) 9/16 (16/9) (n = 42)
Follicular grade I 6
Follicular grade II 9
Follicular grade III 10
Mantle cell lymphoma 5
Average age (males/females) 61 (3/2) WF intermediate-grade
Stage I–II/III–IV (A/B status) 1/4 (3/2) (n = 20)
Diffuse large B-cell lymphoma 18
Average age (males/females) 60 (8/10)
Stage I–II/III–IV (A/B status) 10/8 (11/7)
Precursor B-lymphoblastic leukaemia–lymphoma 6 Kiel high-grade
Average age (males/females) 51 (2/4) (n = 29) WF high-grade
Stage I–II/III–IV (A/B status) 3/3 (2/4) (n = 24)
Burkitt’s lymphoma 5
Average age (males/females) 50 (2/3)
Stage I–II/III–IV (A/B status) 3/2 (3/2)
Lymphadenopathies 30
Average age (males/females) 60 (16/14)
Reactive lymphoid hyperplasias 16
Lymphadenitidesc 8
Dermatopathic lymphadenopathies 4
Rheumatoid lymphadenopathies 4
Atypical lymphoid hyperplasias 14
Associated with systemic lupus erythematosus 9
Associated with common variable immunodeficiency 5
aREAL, Revised European–American Lymphoma classification (Chan, 1994). bAccording to the Ann Arbor system (Carbone et al, 1971). cFour
caused by Epstein–Barr virus, two by human immunodeficiency virus, one by cytomegalovirus, three by Toxoplasma gondii. dMalignancy grades
according to the Kiel Classification (Lennert and Feller, 1992) and the Working Formulation (WF) for Clinical Usage (1982). Five and 13 samples
of diffuse large B-cell lymphomas were allocated to the WF intermediate-grade and high-grade respectively.
}
}
}
}
}was analysed, and because the transversally sectioned microvessels
hit the intersection points randomly, the modified method produced
objective counts. Means ±1 standard deviation (s.d.) were deter-
mined for each section, sample and groups of samples.
Macrophages highlighted by CD68 staining were counted on
6–8 250´ fields (0.25 mm2) covering the whole of each of the three
sections adjacent to those stained for microvessels, and calculated
as means ±1 s.d. for each section, sample and groups of samples.
Electron microscopy
Small pieces (~ 1 mm3) of tissue were fixed in 3% glutaraldehyde
in 0.1M phosphate-buffered saline (PBS) for 3 h, washed in the
same buffer for 12 h, post-fixed in 1% osmium tetroxide, dehy-
drated in graded ethanols and embedded in Epon 812. Ultrathin
sections were cut with a diamond knife on a LKB ultratome,
stained with uranyl acetate followed by lead citrate and examined
in a 9A Zeiss electron microscope (Zeiss, Oberkochen, Germany).
Statistics
The significance of changes in microvessel and macrophage
counts in each group was assessed by parametric (Fisher’s test)
and non-parametric (Kruskal–Wallis’ test) analysis of variance.
Because this showed that some changes were significant, it was
followed by Duncan’s, Bonferroni’s and Wilcoxon’s (t) tests (at
95% confidence interval) to compare groups two by two.
Correlations between microvessel and macrophage counts were
assessed with the Pearson’s (r) coefficient and simple regression
analysis. Mean ± 1 s.d., medians and intervals of variation were
also determined. Data were computed with Statistical Analysis
Software (SAS, SAS Institute, Cary, NC, USA).
RESULTS
Table 2 shows the counts of microvessels and macrophages on
adjacent tissue sections of benign lymphadenopathies and B-
NHLs as a whole and grouped in the Kiel and WF malignancy
grades. The comparison of microvessel counts between groups
revealed statistically significant differences (chi-squared = 46.3,
d.f. = 3, P < 0.001, F = 62.9, P < 0.001). When differences were
sought between groups, significantly higher counts were found in
overall B-NHLs compared with lymphadenopathies (P < 0.001).
Assessment by grades showed a significant increase in Kiel low-
grade tumours compared with lymphadenopathies (P < 0.01) and
yet another in high-grade tumours (P < 0.01). Similar increments
were found in WF low-grade tumours over lymphadenopathies
and in intermediate-grade over low-grade tumours, and (albeit not
significant) in high-grade tumours. In parallel, the macrophage
counts varied significantly between groups (chi-squared = 44.7,
d.f. = 3, P < 0.001; F = 69.1, P < 0.001). The intergroup compar-
isons showed that the counts increased significantly in B-NHLs as
a whole compared with lymphadenopathies (P < 0.001). Also, they
were significantly higher in Kiel low-grade B-NHLs than in
lymphadenopathies (P < 0.05), and in high-grade B-NHLs than in
low-grade B-NHLs (P < 0.01). Similar relationships were found to
the WF malignancy grades. The differences in microvessel and
macrophage density between representative tissue samples are also
shown in Figure 1. The within-group comparisons showed that
both counts were always significantly correlated (Figure 2).
Macrophages were generally scattered throughout the B-NHL
tissue, closely interwoven with tumour cells, and many rested in
the interstitial stroma near or around blood or lymphatic capillaries
(Figure 3A). There was a very close relationship between
macrophages and microvascular endothelial cells, as assessed by
electron microscopy (Figure 3B).
DISCUSSION
The results show that B-NHLs have a higher degree of vascular-
ization than benign lymphadenopathies, and that high-grade
lymphomas have a higher vessel density than those of low grade.
The results also show that macrophage infiltration increases in
parallel with malignancy grade and is highly correlated with the
extent of angiogenesis.
The association between angiogenesis and Kiel and WF malig-
nancy grades suggests that angiogenesis increases with tumour
progression in B-NHLs. These grading systems map out a progres-
sion pathway marked by large increments in tumour cell growth,
as evaluated by S-phase fraction. Kiel low-grade B-NHLs display
S-phase fractions <5%, whereas Kiel high-grade tumours (Czader
et al, 1995; Mochen et al, 1997) and those in transition from WF
low- to intermediate- and high-grade exhibit S-phase fractions
³ 10% (Joensuu et al, 1990). Because angiogenesis favours tumour
growth (Fox, 1997), this could thus complete a positive loop in
B-NHLs.
B-NHL-associated angiogenesis requires endothelial cell prolif-
eration and chemotaxis (needed for vascular sprouting) (Risau,
1997), probably induced by secretion of angiogenic factors
(Watanabe et al, 1997). Both haematic and lymphatic endothelial
cells of node tissues have been shown to proliferate and migrate in
vitro in response to angiogenic factors such as interleukin 6 (IL-6),
basic fibroblast growth factor (FGF-2) and vascular endothelial
growth factor (VEGF-A) (Pepper et al, 1994). B-NHL cells have
been shown to secrete IL-6 (Brach and Hermann, 1992), IL-8 (di
Celle et al, 1994), FGF-2, VEGF-A (Vacca et al, 1998) and tumour
necrosis factor-a (TNF-a) (Adami et al, 1994). In addition, the
peritumoral inflammatory infiltrate surrounding the newly formed
small blood and lymphatic vessels in the stroma of B-NHLs
consists of fibroblasts, macrophages and other leukocytes that may
contribute to the induction of the angiogenic response by secreting
these and other factors (Folkman and Brem, 1992). Macrophages
are strikingly associated with angiogenesis, as found in chronic
inflammation associated with rheumatoid arthritis (Koch et al,
1986), psoriasis (Wolfe, 1989), atherosclerotic plaque (Sueishi et
al, 1990) and in tumours, namely colon (Takahashi et al, 1996),
breast (Leek et al, 1996), ovarian (Sheid, 1992) and renal (Xu et al,
1997) carcinomas. In tumours, macrophages are recruited and acti-
vated via several factors secreted by tumour cells: the chemokines
(Rollins, 1997), as well as FGF-2 and VEGF-A (Watanabe et al,
1997), which are operative at picomolar concentrations. In both
inflammatory and tumour tissues, activated macrophages have
been shown to secrete several angiogenic factors, such as IL-8,
FGF-2, VEGF-A, TNF-a, epidermal growth factor, tissue factor,
hepatocyte growth factor/scatter factor and insulin-like growth
factor-1 (Sunderkötter et al, 1994; Leek et al, 1997). Tentatively,
we suggest that an increasing number of macrophages may be
recruited and activated locally by more malignant B-cells, and that
angiogenesis associated with B-NHLs may be induced, at least
partly, by macrophages via their angiogenic factors.
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Figure 1 Adjacent sections of a benign lymphadenopathy and B-NHL nodes stained with factor VIII for microvessels (A, C, E, G) and with CD68 for
macrophages (B, D, F and H). (A and B) Reactive lymphoid hyperplasia. (C and D) WF low-grade (REAL, small lymphocytic). (E and F) WF intermediate-grade
(REAL, mantle cell lymphoma). (G and H) WF high-grade (REAL, diffuse large B-cell lymphoma) B-NHL. Note the progressive increase of microvessels and
macrophages from A and B to G and H. Bar = 30 mmAngiogenesis and macrophages in B-NHL 969
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Figure 2 Comparison of microvessel and macrophage counts. Significance
of the regression analysis was calculated by Pearson’s r-test. LG, low-grade;
IG, intermediate-grade; HG, high-grade
A
B
Figure 3 Sections of a high-grade (REAL, diffuse large B-cell lymphoma)
B-NHL node showing (A) numerous CD68-reactive macrophages irregularly
scattered throughout the tumour and in close association with a microvessel
(arrowhead), and (B) a macrophage in close vicinity with microvessels
(arrowhead) by electron microscopy. Bar in A = 6 mm, in B = 0.07 mm
Table 2 Tissue density of microvessels and macrophages
Benign
B-cell non-Hodgkin’s lymphomas
lymphadenopathies All Kiel Working formulation
Low-grade High-grade Low-grade Intermediate-grade High-grade
No. of n = 30 n = 71 (n = 42) (n = 29) (n = 27) (n = 20) (n = 24)
Microvessels 3 ± 11 1   ± 5*** 8 ± 3** 14 ± 4† 7 ± 2** 12 ± 3† 14 ± 5
(per 0.78 mm2) (4, 1–6) (10, 3–26) (9, 3–18) (14, 8–26) (7, 3–11) (12, 9–18) (14, 8–26)
Macrophages 2 ± 16   ± 3*** 5 ± 2* 9 ± 3† 4 ± 1* 7 ± 3† 10 ± 3†
(per 0.25 mm2) (2, 0–5) (6, 1–18) (4, 1–12) (9, 5–18) (4, 1–7) (7, 3–14) (10, 5–18)
Results are expressed as mean ± 1 s.d. (median, interval of variation). ***P < 0.001, **P < 0.01 and *P < 0.05 compared with benign lymphadenopathies;
†P < 0.01 compared with the preceding group.ACKNOWLEDGEMENTS
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